AVENLET-2.5

Description

• Active Ingredient: Letrozole IP 2.5 mg.
• Indications:
  • Treatment of hormone receptor-positive breast cancer in postmenopausal women
  • Adjuvant treatment of early breast cancer
  • Extended adjuvant treatment of early breast cancer after standard tamoxifen therapy
  • First-line treatment of advanced breast cancer
• Mechanism of Action: Letrozole is an aromatase inhibitor that works by reducing the amount of estrogen produced in the body. By inhibiting the aromatase enzyme, it lowers estrogen levels, which helps slow or reverse the growth of hormone-sensitive tumors.
• Benefits:
  • Effective in reducing estrogen levels, which can help slow the growth of hormone receptor-positive breast cancer.
  • Suitable for both early and advanced stages of hormone receptor-positive breast cancer.
  • Can be used as an adjuvant treatment after surgery or as a first-line treatment for advanced cases.
• Precautions: Not recommended for individuals with a known hypersensitivity to letrozole or any other components of the formulation. Use with caution in patients with liver or kidney impairment. Letrozole is contraindicated in premenopausal women, during pregnancy, and breastfeeding. Regular monitoring of bone mineral density may be required during long-term therapy due to the risk of osteoporosis.